Overview

* Medifast Q2 2025 revenue falls 37% yr/yr but beats analyst expectations, per LSEG data

* Net income for Q2 2025 at $2.5 mln, aided by LifeMD stock gain

* Co focuses on coach growth and productivity initiatives amid revenue decline

Outlook

* Medifast expects Q3 2025 revenue between $70 mln and $90 mln

* Company anticipates Q3 2025 diluted EPS between ($0.60) and $0.00

Result Drivers

* COACH DECLINE - Revenue fell due to a 32.7% decrease in active earning OPTAVIA coaches, driven by client acquisition challenges

* CLIENT ACQUISITION - Continued pressure on client acquisition affected average revenue per coach, reflecting broader market challenges

* GLP-1 IMPACT - Rapid adoption of GLP-1 medications for weight loss contributed to revenue decline

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $105.56 $96.10

Revenue mln mln (1

Analyst)

Q2 EPS $0.22

Q2 Net $2.48

Income mln

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the food processing peer group is "buy."

* Wall Street's median 12-month price target for Medifast Inc ( MED ) is $15.00, about 8.3% above its August 1 closing price of $13.75

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)